Intrahepatic circulatory time analysis of an ultrasound contrast agent in liver cirrhosis

Liver International

Volumn 25, Issue 2, 2005, Pages 337-342

  Hirota, Masashi ^a   Kaneko, Tetsuya ^a   Sugimoto, Hiroyuki ^a   Kure, Shigehiro ^a   Inoue, Soichiro ^a   Takeda, Shin ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Compensated cirrhosis; Intrahepatic circulatory time; Microbubble contrast agent; Pulse inversion imaging; Ultrasound

Indexed keywords

ECHO CONTRAST MEDIUM; HYALURONIC ACID; SHU 508;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; FEMALE; HEMODYNAMICS; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; NON INVASIVE MEASUREMENT; PORTAL VEIN; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TIME;

ADULT; AGED; BIOLOGICAL AVAILABILITY; CASE-CONTROL STUDIES; CONTRAST MEDIA; FEMALE; HUMANS; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER;

EID: 17044437828     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01085.x     Document Type: Article

References (21)

1. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multi-centre retrospective study on 68 276 biopsies. J Heptol 1986; 2: 165-73.
2. McGill D B, Rakela J, Zinsmeister A R, Ott BJ. A 21-year experience with major hemorrhage after percutancous liver biopsy. Gastroenterology 1990; 99: 1396-400.
3. Gilmore I T, Burroughs A, Murray-Lyon I M, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the BSG and RCP of London. Gut 1995; 36: 437-41.
4. Nord J H. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques - a review. Gastrointest Endosc 1982; 28: 102-4.
5. Oberti F, Valsesia E, Pilette C, et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterolgy 1997; 113: 1609-16.
6. Albrecht T, Blomley M J K, Cosgrove D O, et al. Noninvasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-83.
7. Sugimoto H, Kaneko T, Hirota M, et al. Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intrahepatic hemodynamic changes accompanying cirrhosis. J Hepatol 2002; 37: 578-83.
8. Knodell R G, Ishak K G, Black W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
9. Iijima T, Aoyagi T, Iwao Y, et al. Cardiac output and circulating blood volume analysis by pulse dye-densitometry. J Clin Monit 1997; 13: 81-9.
10. Blomley M J K, Cosgrove D O. Microbubble echoenhancers: a new direction for ultrasound? Lancet 1997; 349: 1855-6.
11. Bang N, Nielsen M B, Rasmussen A N, et al. Hepatic vein transit time of an ultrasound contrast agent: simplified procedure using pulse inversion imaging. Br J Radiol 2001; 74: 752-5.
12. Simpson D H, Burns P N. Pulse inversion Doppler: a new method for detecting nonlinear echoes from microbubble contrast agents. Proc IEEE Ultrason Symp 1997; 1597-600.
13. Burns P N, Wilson S R, Simpson D H. Pulse inversion imaging of liver blood flow: improved method for characterizing focal masses with microbubble contrast. Invest Radiol 2000; 35: 58-71.
14. Eriksson S, Fraser J R E, Laurent T C, et al. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res 1983; 144: 223-8.
15. Smesrød B, Pertoft H, Eriksson S, et al. Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J 1984; 223: 617-26.
16. Engström-Laurent A, Lööf L, Nyberg A, Schröder T. Increased serum levels of hyaluronate in liver disease. Hepatology 1985; 4: 638-42.
17. Guéchot J, Poupon R E, Giral P, et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388-93.
18. Parés A, Deulofeu R, Giménez A, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399-403.
19. Murawaki Y, Ikuta Y, Koda M, et al. Clinical significance of serum hyaluronan in patients with chronic viral liver disease. J Gastroenterol Hepatol 1996; 11: 459-65.
20. Gibson P R, Fraser J R E, Brown T J, et al. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology 1992; 15: 1054-9.
21. Blomely M J K, Lim A K P, Harvey C J, et al. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: a cross sectional study. Gut 2003; 52: 1188-93.